-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

642.O2.6 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter’s Transformation

Symposia: Chronic Lymphocytic Leukemia: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, Research, Acute Myeloid Malignancies, Biological therapies, Antibody Therapy, clinical trials, adult, CLL, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Lymphomas, B Cell lymphoma, Combination therapy, Clinical Research, drug development, Chronic Myeloid Malignancies, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Saturday, December 10, 2022: 4:00 PM-5:30 PM
R06-R09 (Ernest N. Morial Convention Center)
Moderators:
Paolo Ghia, MD, PhD, Universita' Vita-Salute San Raffaele C.F. 97187560152 and Bita Fakhri, MD, MPH, Stanford University
Disclosures:
Ghia: Lilly/Loxo: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; BMS: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. Fakhri: Loxo-Lilly: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Consultancy, Ended employment in the past 24 months; Juno: Membership on an entity's Board of Directors or advisory committees, Research Funding; Angiocrine: Ended employment in the past 24 months, Research Funding.
This oral abstract session includes 4 abstracts reporting results from clinical trials testing targeted triplet combinations in CLL (ibrutinib or acalabrutinib plus venetoclax and obinutuzumab) and 2 abstracts reporting novel agents in Richter's transformation.
4:00 PM

Henriette Huber, MD1,2*, Eugen Tausch, MD2*, Christof Schneider, MD2*, Simone Edenhofer, MD3*, Julia Von Tresckow, MD4,5*, Sandra Robrecht, PhD6*, Adam Giza6*, Can Zhang, PhD7*, Moritz Furstenau, MD8, Peter Dreger, MD9*, Matthias Ritgen, MD10*, Thomas Illmer, MD11, Anna Lena Illert, MD12*, Jan Dürig, MD13*, Sebastian Böttcher, MD, PhD14*, Carsten Utoft Niemann, MD, PhD15, Michael Kneba, MD, PhD16, Anna-Maria Fink, MD8*, Kirsten Fischer, MD17*, Hartmut Döhner, MD18, Michael Hallek, MD19, Barbara Eichhorst, MD20 and Stephan Stilgenbauer, MD21

1Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
2Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
3Ulm University Hospital, Ulm, DEU
4Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Essen, Germany
5Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf; Cologne, University of Cologne, Koeln, Germany
6Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany
7Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany, Cologne, Germany
8Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
9Department of Medicine V, University of Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany
10Department of Internal Medicine II, University of Schleswig-Holstein, Kiel, Germany
11BAG/Onkologische Schwerpunktpraxis, Dresden, Germany
12Department of Internal Medicine I, University Medical Center Freiburg, Freiburg, Germany
13Department of Hematology, Essen University Hospital, Essen, Germany
14Clinic III - Special Hematology Laboratory, University Medical School, Rostock, Rostock, Germany
15Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
16Univ. Schleswig-Holstein, Campus Kiel, Kiel, Germany
17Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
18Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
19Department of Internal Medicine I, Leukapheresis and Stem Cell Transplant Unit, University Hospital of Cologne, Cologne, Germany
20Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Cologne, Germany
21Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany

4:15 PM

Christine E. Ryan, MD1, Benjamin L. Lampson, MD, PhD1, Svitlana Tyekucheva, PhD2*, Liam R. Hackett, AB1*, Yue Ren, MS2*, Samantha J. Shupe, BS1*, Stacey M. Fernandes, BS1*, Jennifer L. Crombie, MD1*, Samuel Ng, MD, PhD1*, Austin I. Kim, MD1, Inhye E. Ahn, MD3, Matthew J Weinstock, MD4, Samantha Pazienza, BS1*, Josie S. Montegaard, NP1*, Victoria Patterson, RN1*, Caron A. Jacobson, MD1, Ann S. LaCasce, MD1, Philippe Armand, MD, PhD1, David C. Fisher, MD1*, Jon E. Arnason, MD5, Steve Lo, MD6*, Adam Olszewski, MD7*, Jennifer R. Brown, MD, PhD1 and Matthew S. Davids, MD1

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
3Dana-Farber Cancer Institute, Boston, MA
4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
5Hematologic Malignancy and Bone Marrow Transplantation Program, Beth Israel Deaconess Medical Center, Boston, MA
6Stamford Hospital, Stamford, CT
7Division of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, RI

4:30 PM

Eugen Tausch, MD1, Christof Schneider, MD1*, Moritz Furstenau, MD2, Sandra Robrecht, PhD3*, Deyan Yordanov Yosifov, PhD1,4*, Daniel Mertens, PhD1,5*, Michael Gregor, MD6*, Patrick Thornton, MB, FRCPath7*, Philipp B. Staber, MD, PhD8, Tamar Tadmor, MD9*, Mark-David Levin10, Caspar da Cunha-Bang11*, Christian Bjørn Poulsen, MD12*, Thomas Illmer, MD13*, Björn Schöttker14*, Ann Janssens, MD, PhD15*, Ilse Christiansen16*, Thomas Noesslinger, MD17, Michael Baumann, MD18*, Clemens-Martin Wendtner19, Eric Eldering, PhD20*, Karl-Anton Kreuzer, MD2*, Matthias Ritgen, MD21*, Anna-Maria Fink, MD2*, Kirsten Fischer, MD2*, Arnon P. Kater, MD, PhD22, Carsten Utoft Niemann, MD, PhD11, Michael Hallek, MD23, Barbara Eichhorst, MD2 and Stephan Stilgenbauer, MD1

1Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
2Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
3Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany
4Department of Molecular Genetics (B061) Cooperation Unit "Mechanisms of Leukemogenesis", German Cancer Research Center (DKFZ), Heidelberg, Germany
5Mechanisms of Leukemogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany
6Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
7Department of Haematology, Beaumont Hospital, Dublin, Ireland
8Medical University Vienna, Vienna, Austria
9Bnai Zion Medical Center, Haifa, Israel
10Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, Netherlands
11Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
12Department of Haematology, Zealand University Hospital, Roskilde, Denmark
13BAG Freiberg-Richter, Jacobasch, Wolf, Illmer,, Hematology-Oncology Practice, Dresden, Germany
14Hämatologisch Onkologische Schwerpunktpraxis, Würzburg, DEU
15Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
16Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
173rd Med. Dept. for Hematology and Oncology, Hanusch Krankenhaus Wien, Wien, Austria
18Department of Oncology, Kantonsspital St. Gallen, St. Gallen, St. Gallen, Switzerland
19Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany
20Department of Experimental Immunology, AMC Amsterdam, Amsterdam, Noord Holland, Netherlands
21Department of Internal Medicine II, University of Schleswig-Holstein, Kiel, Germany
22Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
23Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany

4:45 PM

Moritz Furstenau, MD1, Yvonne Thus2*, Sandra Robrecht, PhD3*, Clemens Mellink4*, Anne-Marie Van Der Kevie-Kersemaekers5*, Julie M.N. Dubois, MD, PhD6*, Julia Von Tresckow, MD7*, Michaela Patz8*, Michael Gregor, MD9*, Patrick Thornton, MB, FRCPath10*, Philipp B. Staber, MD, PhD11, Tamar Tadmor, MD12*, Mark-David Levin13, Caspar Da Cunha-Bang, MD, PhD14, Christof Schneider, MD15*, Christian Bjørn Poulsen, MD16*, Thomas Illmer, MD17, Björn Schöttker18*, Ann Janssens, MD, PhD19*, Ilse Christiansen20*, Michael Baumann, MD21*, Thomas Noesslinger, MD22, Josien Regelink, MD23*, Ellen C Dompeling24*, Vesa Lindström, MD25*, Gunnar Juliusson, MD, PhD26, Anouk Widmer27*, Jeroen Simon Goede28*, Neta Goldschmidt, MD29*, Florian Simon, MD1*, Nisha De Silva, MBBS, MRCP, FRCPath30*, Anna-Maria Fink, MD31*, Kirsten Fischer, MD30*, Clemens-Martin Wendtner32, Matthias Ritgen, MD33*, Monika Brüggemann, MD34*, Eugen Tausch, MD35, Stephan Stilgenbauer, MD36, Eric Eldering, PhD37*, Carsten Utoft Niemann, MD, PhD38, Michael Hallek, MD39,40, Barbara Eichhorst, MD41, Karl-Anton Kreuzer, MD1* and Arnon P. Kater, MD, PhD42

1Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany
2Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, AL, NLD
3Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany
4Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
5Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
6Department of Hematology, Amsterdam University Medical Centers, Amsterdam, Netherlands
7Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Essen, Germany
8University Hospital Cologne, Cologne, DEU
9Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
10Department of Haematology, Beaumont Hospital, Dublin, Ireland
11Medical University Vienna, Vienna, Austria
12Bnai Zion Medical Center, Haifa, Israel
13Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, Netherlands
14Department of Hematology, Rigshospitalet, Copenhagen University Hospital, København Ø, Denmark
15Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
16Department of Haematology, Zealand University Hospital, Roskilde, Denmark
17BAG/Onkologische Schwerpunktpraxis, Dresden, Germany
18Hämatologisch Onkologische Schwerpunktpraxis, Würzburg, DEU
19Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
20Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
21Department of Oncology, Kantonsspital St. Gallen, St. Gallen, St. Gallen, Switzerland
223rd Med. Dept. for Hematology and Oncology, Hanusch Krankenhaus Wien, Wien, Austria
23Department of Haematology, Meander Medisch Centrum, Amersfoort, Amersfoort, NLD
24Isala Ziekenhuis, Zwolle, Netherlands
25Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland
26Skanes University Hospital, Lund, Sweden
2726Department of Medical Oncology and Haematology, USZ, Zürich, Zürich, Switzerland
28Division of Hematology, Kantonsspital Winterthur, Winterthur, Switzerland
29Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
30Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany, Cologne, Germany
31Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group,, University of Cologne, Cologne, Germany
32Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Munich, Germany
33Department of Internal Medicine II, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
34University Medical Center Schleswig-Holstein, Kiel, Germany
35Department of Internal Medicine III, University of Ulm, Ulm, Baden-Württemberg, Germany
36Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
37Department of Experimental Immunology, AMC Amsterdam, Amsterdam, Noord Holland, Netherlands
38Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
39CECAD (Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases), Cologne, Germany
40Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany
41Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany
42Academic Medical Center, Amsterdam Zuidoost, NH, Netherlands

5:00 PM

William G. Wierda, MD, PhD1, David John Lewis, MBChB, PhD2*, Paolo Ghia, MD, PhD3, Nirav N. Shah, MD4, Catherine C. Coombs, MD5, Chan Yoon Y. Cheah, MD6, Nicole Lamanna, MD7, Joanna M. Rhodes, MD, MSCE8, Marc Hoffmann, MD9, Shuo Ma, MD10, Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD11*, Talha Munir, MBBS, MRCP, FRCPath, PhD12*, Manish R. Patel, MD13, Alvaro J. Alencar, MD14, Constantine S. Tam, MD, MBBS15, John F. Seymour, MBBS, PhD, FRACP16, Wojciech Jurczak17, Ewa Lech-Marańda, MD, PhD18*, Lindsey Roeker, MD19, Philip A. Thompson, MBBS1, Paolo B. Abada, MD, PhD20*, Chunxiao Wang, PhD21*, Binoj Nair, PhD20*, Hui Liu, MD, PhD20*, Donald E. Tsai, MD, PhD20* and Anthony R. Mato, MD, MSCE19

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom
3Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
4Medical College of Wisconsin, Brookfield, WI
5University of North Carolina at Chapel Hill, Chapel Hill, NC
6Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, WEA, Australia
7New York-Presbyterian/ Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY
8Northwell Health Cancer Institute, New Hyde Park, NY
9The University of Kansas Cancer Center, Kansas City, KS
10Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
11Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
12Department of Haematology, St. James's University Hospital, Leeds, United Kingdom
13Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL
14Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
15Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia
16Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia
17Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
18Institute of Hematology and Transfusion Medicine, Warsaw, Poland
19Memorial Sloan Kettering Cancer Center, New York, NY
20Loxo@Lilly, Indianapolis, IN
21Eli Lilly and Company, Indianapolis, IN

5:15 PM

Arnon P. Kater, MD, PhD1, J Christine Ye, MD, MSc2, Jose Sandoval-Sus, MD3, Mar Bellido, MD, PhD4*, Jacob Haaber Christensen, MD, PhD5*, Anthony R. Mato, MD, MSCE6, Ann Janssens, MD, PhD7*, Toshihiko Oki, MD, PhD8*, Daniela Hoehn, MD, PhD9, Marcia Rios, MBA9*, Alexandra Kuznetsova, PhD10*, Rebecca Valentin, MD, PhD10* and Herbert Eradat, MD11

1Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands
2Rogel Cancer Center, University of Michigan, Ann Arbor, MI
3Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Moffitt Cancer Center, Pembroke Pines, FL
4Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
5Odense University Hospital, Odense, Denmark
6Memorial Sloan Kettering Cancer Center, New York, NY
7Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
8AbbVie, North Chicago, IL
9Genmab, Princeton, NJ
10Genmab, Copenhagen, Denmark
11David Geffen School of Medicine at UCLA, Los Angeles, CA

*signifies non-member of ASH